Q32 Bio Inc. (QTTB) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Wait for pullback to $14.90. BUY gates pass at $15.68, but the engine prefers a shallower entry for a wider margin of safety. Engine's entry $14.90 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart... Read more
Wait for pullback to $14.90. BUY gates pass at $15.68, but the engine prefers a shallower entry for a wider margin of safety. Engine's entry $14.90 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 63% MoS with quality 8.3. (held at prior verdict — engine reading is near the momentum/RSI threshold; will commit on clearer signal). Score 6.9/10, moderate confidence.
Passes 9/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst cluster(3), earnings proximity no date, semi cycle peak clear, materials cycle peak clear, sector concentration cap sector=healthcare 3/10). Suitability: speculative.
Recent developments
updated 2026-08-01Recent Developments — Q32 Bio Inc.
Latest news
- NEWS QTTB|Q32 Bio Inc|Price:15.670|Chg%:+0.460 - TradingKey — TradingKey neutral
- NEWS QTTB|Q32 Bio Inc|Price:15.670|Chg%:+0.460 - tradingkey.com — tradingkey.com neutral
- NEWS Q32 Bio Inc (QTTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey — TradingKey neutral
- NEWS Q32 Bio Inc (QTTB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey — TradingKey neutral
- NEWS Q32 Bio Inc (QTTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com — tradingkey.com neutral
Generated 2026-08-01T17:17:36Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $14.90. BUY gates pass at $15.68, but the engine prefers a shallower entry for a wider margin of safety. Engine's entry $14.90 (Buy At Market Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No clear chart pattern; technical signals are mixed. Value play: 63% MoS with quality 8.3. (held at prior verdict — engine reading is near the momentum/RSI threshold; will commit on clearer signal). Target $37.82 (+141.2%), stop $11.61 (−35.1%), A.R:R 9.4:1. Score 6.9/10, moderate confidence.
Take-profit target: $37.82 (+141.2% upside). Target $37.82 (+141.2%), stop $11.61 (−35.1%), A.R:R 9.4:1. Stop-loss: $11.61.
Q32 Bio Inc. trades at a P/E of 5.6 (forward -11.0). TrendMatrix value score: 8.1/10. Verdict: Buy (Wait for Entry).
11 analysts cover QTTB with a consensus score of 4.1/5. Average price target: $45.
What does Q32 Bio Inc. do?Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in...
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.